To understand whether inhibiting JAK/STAT3 pathway could increase the sensitivity of human ovarian cancer cells to gefitinib, a recently identified JAKi, AZD1480, was tested for its effect on cell viability when combined with gefitinib. Here, STAT3 is linked to ovarian carcinoma.